Is Sir Christopher Evans selling out? The Welsh Wizard, father of myriad bioscience companies, has just raised a £500m-plus fund that aims to take large stakes in or acquire companies in the European healthcare sector. A major investor in the fund is Sir Tom Hunter, who runs his own private equity firm, West Coast Capital.

Up until now, Sir Christopher has used his own scientific background to help develop and commercialise the newest ideas, with incredible success. His average investment, through his Merlin funds has been £3m to £15m, mainly in early stage research firms. But the new fund aims to invest between £30 and £300 in buyouts and there are rumours of targets already lined up.

What are we to make of this? Few would begrudge a talented and hardworking businessman like Sir Christopher further riches. He is an inspiration to many people and wealth creation is an important part of this. But the very fact he is an inspiration makes this departure a little sad if it means an increasing break from his roots and from the scientists and other researchers who have benefited from his knowledge and experience in the past.

Or perhaps I'm being too sentimental?